Advances in treatment of ulcerative colitis with herbs: From bench to bedside

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14099-14104

  Wan, Ping ^a   Chen, Hao ^a   Guo, Yuan ^a   Bai, Ai Ping ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Herb medicine; Herbs; Inflammatory bowel disease; Safety; Therapy; Ulcerative colitis

Indexed keywords

ALOE VERA EXTRACT; BUTYRIC ACID; CURCUMIN; PLANT EXTRACT; TORMENTIL; TORMENTIL EXTRACT; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ALOE VERA; ARTICLE; BIOLOGICAL ACTIVITY; DRUG SAFETY; HERB; HERBAL MEDICINE; HUMAN; MEDICINAL PLANT; PATHOGENESIS; ULCERATIVE COLITIS; WHEAT; ANIMAL; COLITIS, ULCERATIVE; IMMUNOLOGY; PHYTOTHERAPY; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84910150182     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14099     Document Type: Article

References (51)

1. Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-3182 [PMID: 19086963 DOI: 10.1111/j.1572-0241.2008.02158.x]
2. Chen Q, Zhang H. Clinical study on 118 cases of ulcerative colitis treated by integration of traditional Chinese and Western medicine. J Tradit Chin Med 1999; 19: 163-165 [PMID: 10921142]
3. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007; 59: 1073-1083 [PMID: 17825455 DOI: 10.1016/j.addr.2007.07.003]
4. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005; 206: 260-276 [PMID: 16048554 DOI: 10.1111/j.0105-2896.2005.00291.x]
5. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Bürgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550-564 [PMID: 16083712]
6. Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 2009; 1165: 294-300 [PMID: 19538319 DOI: 10.1111/j.1749-6632.2009.04062.x]
7. Heller F, Fromm A, Gitter AH, Mankertz J, Schulzke JD. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of proinflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 2008; 1 Suppl 1: S58-S61 [PMID: 19079233 DOI: 10.1038/mi.2008.46]
8. Handschick K, Beuerlein K, Jurida L, Bartkuhn M, Müller H, Soelch J, Weber A, Dittrich-Breiholz O, Schneider H, Scharfe M, Jarek M, Stellzig J, Schmitz ML, Kracht M. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-κB-dependent gene expression. Mol Cell 2014; 53: 193-208 [PMID: 24389100 DOI: 10.1016/j.molcel.2013.12.002]
9. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, Mac- Donald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-917 [PMID: 1885073 DOI: 10.1136/gut.32.8.913]
10. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91 [PMID: 1345871 DOI: 10.1016/0140-6736(92)90999-J]
11. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46: 111-123 [PMID: 8926619]
12. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998-1004 [PMID: 8782457 DOI: 10.1038/nm0996-998]
13. Rajilić-Stojanović M, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 2013; 19: 481-488 [PMID: 23385241 DOI: 10.1097/MIB.0b013e31827fec6d]
14. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621 [PMID: 20192811 DOI: 10.1146/annurev-immunol-030409-101225]
15. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298-306 [PMID: 21677746 DOI: 10.1038/nature10208]
16. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
17. Comar KM, Kirby DF. Herbal remedies in gastroenterology. J Clin Gastroenterol 2005; 39: 457-468 [PMID: 15942431 DOI: 10.1097/01.mcg.0000165650.09500.3a]
18. D'Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di Leo V, Buda A, Sturniolo GC. Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. Dig Liver Dis 2007; 39: 524-529 [PMID: 17433794 DOI: 10.1016/j.dld.2007.03.001]
19. Hecht A. The overselling of aloe vera. FDA Consum 1981; 15: 26-29
20. Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther 2004; 19: 521-527 [PMID: 14987320 DOI: 10.1111/j.1365-2036.2004.01874.x]
21. 't Hart LA, Nibbering PH, van den Barselaar MT, van Dijk H, van den Berg AJ, Labadie RP. Effects of low molecular constituents from Aloe vera gel on oxidative metabolism and cytotoxic and bactericidal activities of human neutrophils. Int J Immunopharmacol 1990; 12: 427-434 [PMID: 2167880 DOI: 10.1016/0192-0561(90)90026-J]
22. Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS. Randomized, doubleblind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 739-747 [PMID: 15043514 DOI: 10.1111/j.1365-2036.2004.01902.x]
23. Vermeiren J, Van den Abbeele P, Laukens D, Vigsnaes LK, De Vos M, Boon N, Van de Wiele T. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol Ecol 2012; 79: 685-696 [PMID: 22092917 DOI: 10.1111/j.1574-6941.2011.01252.x]
24. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol 2013; 19: 3404-3414 [PMID: 23801832 DOI: 10.3748/wjg.v19.i22.3404]
25. Vieira EL, Leonel AJ, Sad AP, Beltrão NR, Costa TF, Ferreira TM, Gomes-Santos AC, Faria AM, Peluzio MC, Cara DC, Alvarez-Leite JI. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem 2012; 23: 430-436 [PMID: 21658926 DOI: 10.1016/j.jnutbio.2011.01.007]
26. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA 2014; 111: 2247-2252 [PMID: 24390544 DOI: 10.1073/pnas.1322269111]
27. Lührs H, Gerke T, Schauber J, Dusel G, Melcher R, Scheppach W, Menzel T. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis 2001; 16: 195-201 [PMID: 11515677 DOI: 10.1007/s003840100295]
28. Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403 [PMID: 10940278 DOI: 10.1136/gut.47.3.397]
29. Lührs H, Gerke T, Müller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-466 [PMID: 11989838 DOI: 10.1080/003655202317316105]
30. Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH, Liu K. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1405-G1415 [PMID: 22517765 DOI: 10.1152/ajpgi.00543.2011]
31. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320: 23-28 [PMID: 2909876 DOI: 10.1056/NEJM198901053200105]
32. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, Richter F, Dusel G, Kasper H. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 51-56 [PMID: 1612357]
33. Vernia P, Fracasso PL, Casale V, Villotti G, Marcheggiano A, Stigliano V, Pinnaro P, Bagnardi V, Caprilli R. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000; 356: 1232-1235 [PMID: 11072942 DOI: 10.1016/S0140-6736(00)02787-2]
34. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, Marcheggiano A, Pallone F, Caprilli R, Torsoli A. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000; 45: 976-981 [PMID: 10795763]
35. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol 1996; 91: 731-734 [PMID: 8677939]
36. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German- Austrian SCFA Study Group. Dig Dis Sci 1996; 41: 2254-2259 [PMID: 8943981 DOI: 10.1007/BF02071409]
37. Bos MA, Vennat B, Meunier MT, Pouget MP, Pourrat A, Fialip J. Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti-elastase activity. Biol Pharm Bull 1996; 19: 146-148 [PMID: 8820929 DOI: 10.1248/bpb.19.146]
38. Vennat B, Bos MA, Pourrat A, Bastide P. Procyanidins from tormentil: fractionation and study of the anti-radical activity towards superoxide anion. Biol Pharm Bull 1994; 17: 1613-1615 [PMID: 7735205 DOI: 10.1248/bpb.17.1613]
39. Huber R, Ditfurth AV, Amann F, Güthlin C, Rostock M, Trittler R, Kümmerer K, Merfort I. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 2007; 41: 834-838 [PMID: 17881930 DOI: 10.1097/MCG.0b013e31804b2173]
40. Kulkarni SD, Tilak JC, Acharya R, Rajurkar NS, Devasagayam TP, Reddy AV. Evaluation of the antioxidant activity of wheat-grass (Triticum aestivum L.) as a function of growth under different conditions. Phytother Res 2006; 20: 218-227 [PMID: 16521113 DOI: 10.1002/ptr.1838]
41. Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E, Doseff AI. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol 2007; 179: 7121-7127 [PMID: 17982104]
42. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002; 37: 444-449 [PMID: 11989836 DOI: 10.1080/003655202317316088]
43. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009; 15: 2087-2094 [PMID: 19519446 DOI: 10.2174/138161209788489177]
44. Larmonier CB, Midura-Kiela MT, Ramalingam R, Laubitz D, Janikashvili N, Larmonier N, Ghishan FK, Kiela PR. Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 503-515 [PMID: 20629184 DOI: 10.1002/ibd.21391]
45. Singla V, Pratap Mouli V, Garg SK, Rai T, Choudhury BN, Verma P, Deb R, Tiwari V, Rohatgi S, Dhingra R, Kedia S, Sharma PK, Makharia G, Ahuja V. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014; 8: 208-214 [PMID: 24011514 DOI: 10.1016/j.crohns.2013.08.006]
46. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506 [PMID: 17101300 DOI: 10.1016/j.cgh.2006.08.008]
47. Hallert C, Björck I, Nyman M, Pousette A, Grännö C, Svensson H. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis 2003; 9: 116-121 [PMID: 12769445 DOI: 10.1097/00054725-200303000-00005]
48. Rahimi R, Nikfar S, Abdollahi M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol 2013; 19: 5738-5749 [PMID: 24039370]
49. Shushunov S, Balashov L, Kravtsova A, Krasnogorsky I, Latté KP, Vasiliev A. Determination of acute toxicity of the aqueous extract of Potentilla erecta (Tormentil) rhizomes in rats and mice. J Med Food 2009; 12: 1173-1176 [PMID: 19857087 DOI: 10.1089/jmf.2008.0281]
50. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 341-349 [PMID: 16422993 DOI: 10.1111/j.1365-2036.2006.02761.x]
51. Boudreau MD, Mellick PW, Olson GR, Felton RP, Thorn BT, Beland FA. Clear evidence of carcinogenic activity by a wholeleaf extract of Aloe barbadensis miller (aloe vera) in F344/N rats. Toxicol Sci 2013; 131: 26-39 [PMID: 22968693 DOI: 10.1093/toxsci/kfs275]